相关实验视频

Updated: Jan 14, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

作为结核病潜在免疫调节剂的N-乙半氨酸:在试点研究中证明IL-2升高的证据

Resti Yudhawati^1,2,3, Septiardhi Husodo^1,2,3, Faradila Nur Aini³

¹Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia.

Journal of inflammation research

|October 23, 2025

概括

在结核病患者中,补充N-乙半氨酸 (NAC) 显著提高了互白素-2 (IL-2) 水平. 这表明NAC可以增强免疫反应,并可作为结核病的有效辅助疗法.

科学领域:

免疫学免疫学免疫学
传染性疾病传染性疾病
药理学药理学是指药理学的学科.

背景情况:

结核病 (TB) 仍然是一个重大的全球卫生挑战,需要新的治疗策略.
主体免疫反应在控制Mycobacterium结核病感染方面发挥着至关重要的作用.
介素-2 (IL-2) 是一种关键的细胞因子,参与T细胞介导免疫.

研究的目的:

为了研究N-乙半氨酸 (NAC) 作为一种免疫调节剂.
评估NAC增强宿主免疫应对Mycobacterium结核病的潜力.
为了评估NAC对结核病患者中白素-2 (IL-2) 生产的影响.

主要方法:

进行了一项准实验性研究.
新确诊的肺结核患者被分为治疗组 (NAC) 和对照组.
酶相关免疫吸收试验 (ELISA) 用于测量IL-2水平,并进行统计分析比较组.

主要成果:

在NAC给药之前,在两组之间没有观察到IL-2水平的显著差异.
在NAC治疗组中,治疗后IL-2水平显著增加 (p=0.023).
在NAC组和对照组 (p=0.025) 之间,Delta IL-2水平有显著差异.

结论:

在肺结核患者中,补充N-乙半氨酸 (NAC) 显著增加了IL-2水平.
这些发现表明,NAC可以增强免疫反应.
NAC显示出作为标准结核病治疗的辅助疗法的潜力.

关键词:

在IL-2中,IL-2被认为是IL-2.这是一种N-乙西斯泰因 (N-acetylsistein).抗氧化剂是一种抗氧化剂.免疫调节器是一种免疫调节器.结核病是一种肺结核病.

更多相关视频

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

相关概念视频

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...